TABLE 1.
Antimicrobial susceptibilities of A. bereziniae HPC229 and its plasmid-cured HPC229c derivativec
| Antimicrobial(s) | MIC (μg/ml) |
|
|---|---|---|
| HPC229 | HPC229c | |
| Ampicillin-sulbactama | 16 | ≤2 |
| Ceftazidimeb | ≥256 | 8 |
| Cefotaximea | ≥64 | 8 |
| Cefepimeb | ≥256 | 1 |
| Piperacillin-tazobactama | ≥128 | 8 |
| Imipenemb | 128 | 0.125 |
| Meropenema | ≥16 | 1 |
| Colistina | ≤0.5 | ≤0.5 |
| Gentamicina | ≤1 | ≤1 |
| Amikacina | ≤2 | ≤2 |
| Trimethoprim-sulfamethoxazolea | ≤20 | ≤20 |
| Ciprofloxacina | 0.5 | 0.5 |
a
MICs were determined by the Vitek 2 system.
b
MICs were determined by the agar dilution method.
c
HPC229 was resistant to ampicillin-sulbactam, ceftazidime, cefotaxime, cefepime, piperacillin-tazobactam, imipenem, and meropenem, and it was susceptible to colistin, gentamicin, amikacin, trimethoprim-sulfamethoxazole, and ciprofloxacin according to CLSI breakpoints (10).